Evaluation of the effectiveness of 4% formalin in the treatment of hemorrhagic actinic proctitis

JUVENAL ROCHA TORRES NETO1, ALEX RODRIGUES MOURA2, FÁBIO RAMOS TEIXEIRA2, ANA PAULA ANDRADE MENEZES3, DAM RODRIGUES MARIANO4

1Doctor Professor and Head of the Coloproctology Service at Universidade Federal de Sergipe (UFS) – Aracaju (SE), Brazil. 2Resident doctors of proctology at UFS – Aracaju (SE), Brazil. 3Radiologist at UFS – Aracaju (SE), Brazil. 4Coloproctologist at UFS – Aracaju (SE), Brazil.

ABSTRACT: Radiotherapy is an important discovery as to the treatment of pelvic tumors. Proctitis is frequently observed nowadays, and can be divided into acute and chronic. Treatment with 4% formalin solutions has been used with positive results in literature. Objective: To evaluate the effectiveness and morbidity rates related to the use of 4% formalin in hemorrhagic chronic actinic proctitis. Methods: We evaluated the sigmoidoscopy records and reports of 11 patients with chronic hemorrhagic actinic proctitis from February to December 2010, coming from the Serbian colorectal University Hospital of the State of Sergipe. Results: The study was comprised of 11 patients (36.36% were females and 63.63% were males). Mean age was 67.7 years. Mean time between the end of radiotherapy and the onset of symptoms was 6.6 months. The treatment was completely effective in 27.27% of the cases, and reduced rectal bleeding in 100% of patients. The following main complications were observed: chills (9%), tenesmus (18.18%) and mild stenosis (9%). Conclusions: The 4% formalin solution has fewer side effects, and its administration is very inexpensive. The treatment is effective and reduces bleeding in almost 100% of cases.

Keywords: proctitis; formalin; radiotherapy.

INTRODUCTION

Radiotherapy is part of the healing treatment for many malignant pathologies, such as neoplasm of the rectum, uterus, prostate, bladder, anal canal and margin1,2. Despite the benefits of this procedure, the lesions caused by radiation may cause early and late unwanted effects3, ranging from 5 and 20%.

During the radiotherapy treatment of abdominal or pelvic tumors, the intestine is an important organ at-risk4. The toxicity of the radiation in the intestine is classified as acute and chronic, according to the onset of symptoms. In less than three months, it is considered as acute, and after this time, it is chronic4. The acute complications are mainly caused by injuries of the radiation in the mucosa. This is due to the action of the radiation on the dividing cells, usually leading to self limited lesions. Chronically, the symptoms are owed to the progressive submucosal fibrosis and endoarterial obliteration, leading to the formation of neovascular telangiectasia, causing fragility and bleeding5.

Since the rectum is more fixed and close to the pelvic organs, it is more prone to complications from the radiation3.

Different clinical and surgical therapies may be performed. Derivatives of aminosalicylic acid, corticoid, sucralfate, argon plasma, bipolar electrocoagulation, retinol palmitate, rectal misoprostal, vitamin E,
vitamin C, hyperbaric therapy and different concentrations of formalin are some of the methods used to treat this pathology.\textsuperscript{5-6} The surgical treatment is used in complicated processes, such as obstruction, fistulization or uncontrollable hemorrhage, thus being restricted due to the increased morbimortality rates caused by actinic alterations, which makes the healing more difficult.

Since the 4\% formalin has shown positive outcomes, associated with the low cost, simple use and versatility, it can be used as the first treatment in refractory cases.\textsuperscript{6}

Despite the decreasing incidence of actinic proctitis with the use of more precise radiotherapy devices, there is still a significant number of patients who need outpatient follow-up.

So, the objective was to assess the efficacy and the morbidity rates of the mentioned method, which is already used in the Service of Proctology of the University Hospital of Sergipe, Brazil.

**OBJECTIVES**

Main objective:

• To assess the efficacy and morbidity rates related to the use of 4\% formalin for hemorrhagic chronic actinic proctitis.

Secondary objectives:

• To assess the demographic profile of actinic proctitis;
• To analyze which pathologies led to the need for radiotherapy, causing actinic proctitis;
• Time between the end of radiotherapy and the onset of symptoms.

**MATERIALS AND METHODS**

**Sample**

The medical records of patients coming from the Service of Coloproctology at the University Hospital of Sergipe who presented with hemorrhagic chronic actinic proctitis were analyzed. They were submitted to 4\% formalin from February to December 2012. It was not necessary that the patient signed the informed consent form, since the paper consists only on data collection from medical records.

The study was approved by the Research Ethics Committee of Universidade Federal de Sergipe.

**Statistical analysis**

The collected data will be inserted in a database system; afterwards, they will be submitted to statistical analysis. Simple frequency tables will be used to characterize the results, as well as the median, mean and standard deviation.

**Methodology**

The 4\% formalol solution was administrated via rectosigmoidoscopy. The highest amount of 4\% formalin was 500 mL, administered for 30 s. After the administration, the content was aspirated and irrigated with a 0.9\% physiological solution, 1,000 mL, until the complete withdrawal of the solution.

All patients underwent at least two rectosigmoidoscopies. At first, before the use of formalin, the endoscopic classification was level I (less than 10 telangiectasias), II (more than 10 telangiectasias, with coalescence of 2 telangiectasias at most), III (multiple coalescent telangiectasias), or IV (ulcers) (Figure 1) at the first use of formalin. After one month, the second rectosigmoidoscopy was performed for endoscopic grading, and if the patient had no more complaints, the treatment would be suspended. If the complaints persist, new formalin solutions were used every month until the total remission of the hemorrhage.

**RESULTS**

The study consisted of 11 patients with hemorrhagic chronic actinic proctitis, and 36.36\% of them were males and 63.63\% were females. For males, the basal disease that led to radiotherapy was prostate cancer in 100\% of the cases; for females, the radiotherapy was a result of uterine cervical neoplasm.

Mean age was 67.7 years (ranging from 56 and 66 years), with median of 66.5 years. For males, the mean was 67.75 years, and for females, it was 67.71 years.

Mean time between the end of radiotherapy and the onset of symptoms was 6.6 months, ranging from 1 month to 11 months. The dose and the type (teletherapy and/or brachytherapy) were not accounted for, since most patients did not have the radiotherapy report.

Out of the common endoscopic findings observed among patients, there are: telangiectasis, fri-
ability and small ulcers. Rectal bleeding and sphincter irritability were observed in 100% of the patients; tenesmus, in 80%; diarrhea and mucus in 60% of the cases, and essential hemorrhage in 9% of them. Mild stenosis and a small ulcer in the posterior anal canal were observed in one patient; after the biopsy, the anatomicopathological was compatible with actinic proctitis.

Response to treatment was classified as to the endoscopic classification of the rectosigmoid mucosa in: level I (less than 10 telangiectasias), II (more than 10 telangiectasias, with coalescence of 2 telangiectasias at most), III (multiple coalescent telangiectasias), or IV (ulcers).

In the beginning of the treatment, the findings were 18.18% of level I; 27.27% of level II; 36.36% of level III and 18.18% of level IV. Complications such as perforations and fever were not observed. However, the chills were observed in 9% of the patients, tenesmus, in 18.18% of them, and mild stenosis, in 9%. Only one patient (9%) had to terminate the treatment, since he had aplastic anemia as a complication of radiotherapy.

The treatment was completely effective in 27.27% of the cases. For all other patients, rectal bleeding was significantly reduced. After the beginning of the treatment, hemotransfusion was necessary for only three patients (27.27%). No ostomy was necessary for transit deviation due to uncontrolled bleeding.

Table 1 shows data regarding the patients treated with 4% formalin.

<table>
<thead>
<tr>
<th>Initials</th>
<th>Gender</th>
<th>Age</th>
<th>Neoplasm</th>
<th>Period of Time (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>JCS</td>
<td>F</td>
<td>68</td>
<td>UCN*</td>
<td>7</td>
</tr>
<tr>
<td>AAO</td>
<td>F</td>
<td>75</td>
<td>UCN*</td>
<td>3</td>
</tr>
<tr>
<td>MR</td>
<td>F</td>
<td>56</td>
<td>UCN*</td>
<td>6</td>
</tr>
<tr>
<td>MMS</td>
<td>M</td>
<td>65</td>
<td>PN**</td>
<td>8</td>
</tr>
<tr>
<td>RFL</td>
<td>F</td>
<td>67</td>
<td>UCN*</td>
<td>11</td>
</tr>
<tr>
<td>MJM</td>
<td>M</td>
<td>72</td>
<td>PN**</td>
<td>10</td>
</tr>
<tr>
<td>JAS</td>
<td>M</td>
<td>67</td>
<td>PN**</td>
<td>1</td>
</tr>
<tr>
<td>JBS</td>
<td>M</td>
<td>67</td>
<td>PN**</td>
<td>3</td>
</tr>
<tr>
<td>MFS</td>
<td>F</td>
<td>77</td>
<td>UCN*</td>
<td>4</td>
</tr>
<tr>
<td>MCJ</td>
<td>F</td>
<td>64</td>
<td>UCN*</td>
<td>11</td>
</tr>
<tr>
<td>EBA</td>
<td>F</td>
<td>67</td>
<td>UCN*</td>
<td>9</td>
</tr>
</tbody>
</table>

*Uterine Cervical Neoplasm.
**Prostate Neoplasm.

DISCUSSION

Radiotherapy was a major discovery to treat several diseases, leading to cure without the need for surgery. However, it is not a complication-free procedure. The hemorrhagic chronic actinic proctitis is one of these complications; this pathology leads to great morbidity rates, limiting activities and even mortality.

There is a great range of substances that have been studied for the clinical treatment of this disease (derivatives of aminosalicylic acid, sucralfate, argon plasma, bipolar electrocoagulation, short-chain acids, hyperbaric oxygen and different concentrations of formalin). Due to the great possibility of technical complications, since local fibrosis is caused by the radiation and the adherence of pelvic organs, the surgical treatment is restricted to local complications (fistulae), persistence of symptoms and uncontrollable bleeding.

For patients without surgical roof, it is possible to use the derivation of intestinal transit.

The formalin has been used since the past century. At first, it was used for cases of hemorrhagic cystitis, by Brown, in 1968. It was first introduced by Rubinstein et al. to treat hemorrhagic chronic proctitis at a 3.6% concentration, showing good results. Thus, some papers have been showing the success and safety in using 4% formalin.
In literature, the pathology that is mainly responsible for pelvic radiation was uterine cervical neoplasm, which confirms our study, since it presented 63.63% of the patients with such neoplasm. Most patients with complications presented colorectal alterations, which appear from 12 to 18 months after radiotherapy. Mean time between the onset of hemorrhagic symptoms and the end of radiotherapy was 6.6 months, ranging from 1 to 11 months.

Rectal bleeding, tenesmus, diarrhea, mucus stool, abdominal pain, and sphincter irritability are the more common symptoms of hemorrhagic chronic actinic proctitis. The lower gastrointestinal bleeding caused by telangiectasias may cause severe anemia, leading to the need for multiple hemotransfusions. In our study, three patients (27.27%) needed a hemotransfusion after the administration of 4% formalin.

The concentration of 4% formalin was obtained after observations; some studies showed that such dilution is efficient and presents no adverse effects. The technique of intrarectal administration is safe when the time of contact with rectal mucosa is

In literature, the pathology that is mainly responsible for pelvic radiation was uterine cervical neoplasm, which confirms our study, since it presented 63.63% of the patients with such neoplasm. Most patients with complications presented colorectal alterations, which appear from 12 to 18 months after radiotherapy. Mean time between the onset of hemorrhagic symptoms and the end of radiotherapy was 6.6 months, ranging from 1 to 11 months.

Rectal bleeding, tenesmus, diarrhea, mucus stool, abdominal pain, and sphincter irritability are the more common symptoms of hemorrhagic chronic actinic proctitis. The lower gastrointestinal bleeding caused by telangiectasias may cause severe anemia, leading to the need for multiple hemotransfusions. In our study, three patients (27.27%) needed a hemotransfusion after the administration of 4% formalin.

The concentration of 4% formalin was obtained after observations; some studies showed that such dilution is efficient and presents no adverse effects. The technique of intrarectal administration is safe when the time of contact with rectal mucosa is

In literature, the pathology that is mainly responsible for pelvic radiation was uterine cervical neoplasm, which confirms our study, since it presented 63.63% of the patients with such neoplasm. Most patients with complications presented colorectal alterations, which appear from 12 to 18 months after radiotherapy. Mean time between the onset of hemorrhagic symptoms and the end of radiotherapy was 6.6 months, ranging from 1 to 11 months.

Rectal bleeding, tenesmus, diarrhea, mucus stool, abdominal pain, and sphincter irritability are the more common symptoms of hemorrhagic chronic actinic proctitis. The lower gastrointestinal bleeding caused by telangiectasias may cause severe anemia, leading to the need for multiple hemotransfusions. In our study, three patients (27.27%) needed a hemotransfusion after the administration of 4% formalin.

The concentration of 4% formalin was obtained after observations; some studies showed that such dilution is efficient and presents no adverse effects. The technique of intrarectal administration is safe when the time of contact with rectal mucosa is
about 30 to 60 seconds, and the volume is 400 to 500 mL.\textsuperscript{13}

The complications described in literature range from 0 to 36.36%. In our study, one patient presented with chills, another one had mild stenosis, and two others had tenesmus, accounting for 36.36% of complications. Only one patient had to interrupt the participation in the study due to aplastic anemia as a complication from the radiotherapy.

As to the general effectiveness of the treatment (improvement of symptoms, capacity to control hematocrit and hemoglobin levels, avoiding the need for hemotransfusion), it ranged from 93.1 to 100%; the results in our studies were compatible with literature (100%).

**CONCLUSION**

After the literature review and the results of the use of 4% formalin, it is possible to observe that:

- The treatment of hemorrhagic chronic actinic proctitis is a challenge to the doctors; prevention is the most important step;
- The 4% formalin solution has a few side effects, besides being low-cost.
- The treatment is effective, and reduces the bleeding in almost 100% of the cases.

With these results, we suggest the administration of 4% formalin as an effective treatment for hemorrhagic chronic actinic proctitis.

**REFERENCES**


Correspondence to:
Alex Rodrigues Moura
Rua Itabaiana, 820, Edif. Veleiro, ap. 603 – São José
CEP: 49915-110 – Aracaju (SE), Brazil.
E-mail: alexmoura@ig.com.br